Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

44.18
+0.89002.06%
Post-market: 44.180.00000.00%19:30 EDT
Volume:1.25M
Turnover:54.92M
Market Cap:4.80B
PE:-23.88
High:44.68
Open:43.54
Low:43.00
Close:43.29
52wk High:48.40
52wk Low:13.69
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.94
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:10.71
PE(LYR):-27.10

Loading ...

Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $45 From $34

THOMSON REUTERS
·
Mar 17

Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 16

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Mar 11

Edgewise Therapeutics Says Sevasemten Shows Long-Term Functional Stability in Becker Muscular Dystrophy

MT Newswires Live
·
Mar 10

Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions

TIPRANKS
·
Mar 07

Wedbush Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)

TIPRANKS
·
Mar 06

Edgewise Therapeutics to Present at Leerink Global Healthcare Conference

Reuters
·
Mar 04

Edgewise Therapeutics to Present Sevasemten Becker Muscular Dystrophy Data at 2026 MDA Clinical and Scientific Conference

Reuters
·
Mar 03

Stock Track | Edgewise Therapeutics Plummets 5.19% Intraday Following Q4 Earnings Miss and Inducement Grants

Stock Track
·
Mar 02

Edgewise Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Edgewise Therapeutics Reports Inducement Stock Option Grants Under Nasdaq Rules

Reuters
·
Mar 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Mar 02

Edgewise Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 27

RBC Capital Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)

TIPRANKS
·
Feb 27

Edgewise Therapeutics Q4 EPS $(0.47) Misses $(0.43) Estimate

Benzinga Earnings
·
Feb 27

Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.47 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Feb 26

Edgewise Therapeutics posts Q4 net loss of USD 50.2 million, R&D expenses USD 43.6 million (+16.3%)

Reuters
·
Feb 26

Edgewise Therapeutics Q4 Operating Expenses USD 55.979 Million

THOMSON REUTERS
·
Feb 26

Edgewise Therapeutics Q4 Basic EPS USD -0.47

THOMSON REUTERS
·
Feb 26

Press Release: Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Dow Jones
·
Feb 26